?AHSN Network Programmes
Programme
overlapThe Innovation Agency and the AHSN Network are rolling out programmes of innovation on behalf of our national NHS commissioners. From April 2020 three programmes have been selected for national adoption and spread which have evidence of impact.
Eating Disorders > Early InterventionMHMental Health
ADHD > Improving DiagnosisMHMental Health
Lipid management and FH >CRCardio-respiratory
?
Programme
overlapThe Innovation Agency leads the Patient Safety Collaborative for the North West Coast and delivers the National Patient Safety Improvement Programme in the region.
Read more >>>
Managing Deterioration >
Medicines >
Maternity and Neonatal >MNMaternity and Neonatal
Mental Health >MHMental Health
Adopt and Spread >
?Innovation Agency cardio-respiratory improvement programmes
Programme
overlapCardiovascular disease (CVD) and respiratory disease are Innovation Agency priorities for innovation and improvement from 2020-2023. Find out more >>>
Atrial fibrillation >CRCardio-respiratory
Respiratory >CRCardio-respiratory
Lipid management >CRCardio-respiratory
NHS @home programmes?
Programme
overlapNHS @home is a nationally-led programme of work providing better connected, more personalised care in people’s homes including care homes. It aims to ensure people have faster access to more appropriate and targeted care, without necessarily having to attend emergency care or arrange GP appointments.
NHS @home builds upon what we have learned during the COVID-19 pandemic and aims to maximise the use of technology to support more people to better self-manage their health and care at home. This provides more convenient, high quality and timely alternatives to face to face care, where this works for the individual, and when clinically appropriate.
Find out more >>>
COVID Oximetry @HomeCRCardio-respiratory
COVID virtual wardsCRCardio-respiratory
Proactive Care @HomeCRCardio-respiratory
Blood pressure monitoring @HomeCRCardio-respiratory
Flash glucose monitoring
Rapid Uptake Products (RUPs)?
Programme
overlapThe Rapid Uptake Products (RUP) programme has been designed to support stronger adoption and spread of proven innovations. It identifies and supports products with NICE approval that support the NHS Long Term Plan’s key clinical priorities, but have lower than expected uptake to date. The 2020/21 programme builds on the successes of the 2019/20 RUPs programme, with themes selected via an open, staged, selection process. Find out more >>> [AHSN Network website]
Preeclampsia > Placental growth factor (PIGF) based testsMNMaternity and NeonatalPPMulti-programme product
Coronary heart disease > HeartFlow FFRCT diagnosisCRCardio-respiratoryPPMulti-programme product
Lipid Management > and PCSK9 inhibitorsCRCardio-respiratory
Asthma > Measuring nitric oxide (FeNO) and biologics treatmentCRCardio-respiratory
MedTech Funding Mandate programmes and products?
Programme
overlapThe Innovation Agency and our fellow AHSNs are offering support to technologies that will be supported by the NHS MedTech Funding Mandate 2021/22 policy, some of which are also Rapid Uptake Products. Find out more >>>
Preeclampsia > Placental growth factor (PIGF) based testsMNMaternity and NeonatalPPMulti-programme product
Coronary heart disease > HeartFlow FFRCT diagnosisCRCardio-respiratoryPPMulti-programme product
Catheters > SecurAcath for securing percutaneous catheters
Cluster headache > gammaCore nerve stimulation
